Select your Country or Region

  • TargetMol | Compound LibraryArgentinaArgentina
  • TargetMol | Compound LibraryAustraliaAustralia
  • TargetMol | Compound LibraryAustriaAustria
  • TargetMol | Compound LibraryBelgiumBelgium
  • TargetMol | Compound LibraryBrazilBrazil
  • TargetMol | Compound LibraryBulgariaBulgaria
  • TargetMol | Compound LibraryCroatiaCroatia
  • TargetMol | Compound LibraryCyprusCyprus
  • TargetMol | Compound LibraryCzechCzech
  • TargetMol | Compound LibraryDenmarkDenmark
  • TargetMol | Compound LibraryEgyptEgypt
  • TargetMol | Compound LibraryEstoniaEstonia
  • TargetMol | Compound LibraryFinlandFinland
  • TargetMol | Compound LibraryFranceFrance
  • TargetMol | Compound LibraryGermanyGermany
  • TargetMol | Compound LibraryGreeceGreece
  • TargetMol | Compound LibraryHong KongHong Kong
  • TargetMol | Compound LibraryHungaryHungary
  • TargetMol | Compound LibraryIcelandIceland
  • TargetMol | Compound LibraryIndiaIndia
  • TargetMol | Compound LibraryIrelandIreland
  • TargetMol | Compound LibraryIsraelIsrael
  • TargetMol | Compound LibraryItalyItaly
  • TargetMol | Compound LibraryJapanJapan
  • TargetMol | Compound LibraryKoreaKorea
  • TargetMol | Compound LibraryLatviaLatvia
  • TargetMol | Compound LibraryLebanonLebanon
  • TargetMol | Compound LibraryMalaysiaMalaysia
  • TargetMol | Compound LibraryMaltaMalta
  • TargetMol | Compound LibraryMoroccoMorocco
  • TargetMol | Compound LibraryNetherlandsNetherlands
  • TargetMol | Compound LibraryNew ZealandNew Zealand
  • TargetMol | Compound LibraryNorwayNorway
  • TargetMol | Compound LibraryPolandPoland
  • TargetMol | Compound LibraryPortugalPortugal
  • TargetMol | Compound LibraryRomaniaRomania
  • TargetMol | Compound LibrarySingaporeSingapore
  • TargetMol | Compound LibrarySlovakiaSlovakia
  • TargetMol | Compound LibrarySloveniaSlovenia
  • TargetMol | Compound LibrarySpainSpain
  • TargetMol | Compound LibrarySwedenSweden
  • TargetMol | Compound LibrarySwitzerlandSwitzerland
  • TargetMol | Compound LibraryTaiwan,ChinaTaiwan,China
  • TargetMol | Compound LibraryThailandThailand
  • TargetMol | Compound LibraryTurkeyTurkey
  • TargetMol | Compound LibraryUnited KingdomUnited Kingdom
  • TargetMol | Compound LibraryUnited StatesUnited States
  • TargetMol | Compound LibraryOther CountriesOther Countries
Shopping Cart
  • Remove All
  • TargetMol
    Your shopping cart is currently empty

Factor Xa

Factor X, also known by the eponym Stuart–Prower factor, is an enzyme  of the coagulation cascade. It is a serine endopeptidase (protease group S1, PA clan). Factor X is synthesized in the liver and requires vitamin K for its synthesis.Factor X is activated, by hydrolysis, into factor Xa by both factor IX (with its cofactor, factor VIII in a complex known as intrinsic Tenase) and factor VII with its cofactor, tissue factor (a complex known as extrinsic Tenase ). It is therefore the first member of the final common pathway or thrombin pathway.

  • Coumarin
    T077591-64-5
    Coumarin is a chemical compound/poison found in many plants, notably in high concentration in the tonka bean, woodruff, and bison grass. It has clinical value as the precursor for several anticoagulants, notably warfarin.
    • $33
    In Stock
    Size
    QTY
  • Heparin sodium salt
    T65319041-08-1
    Heparin sodium is a sulfated polysaccharide, which belongs to the family of glycosaminoglycans. It is utilized as an anticoagulant and interacted with diverse proteins for numerous important biological activities.Heparin sodium salt (Sodium heparinate) significantly inhibits exosome-cell interactions.
    • $41
    In Stock
    Size
    QTY
    TargetMol | Citations Cited
  • Zifaxaban
    T292151378266-98-8In house
    Zifaxaban (TY-602) is an orally active, competitive and selective inhibitor of factor Xa (FXa) with an IC50 of 11.1 nM for human FXa.Zifaxaban has a very high affinity, more than 10,000-fold higher than that of other serine proteases.Zifaxaban can be used to study arterial and venous thrombosis.
    • $350
    In Stock
    Size
    QTY
  • LY 517717
    T27920313489-71-3In house
    LY 517717 is an orally active inhibitor of coagulation factor Xa with antithrombotic activity for the study of venous thromboembolism (VTE).
    • $293 TargetMol
    In Stock
    Size
    QTY
  • 4-Chlorophenylurea
    T20454140-38-5
    4-Chlorophenylurea (NSC-12971) is a novel orally bioavailable inhibitor of factor Xa.
    • $40
    In Stock
    Size
    QTY
  • Ethyl 1-(4-methoxyphenyl)-7-oxo-6-(4-(2-oxopiperidin-1-yl)phenyl)-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxylate
    T66256503614-91-3
    Ethyl 1-(4-methoxyphenyl)-7-oxo-6-(4-(2-oxopiperidin-1-yl)phenyl)-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxylate has an inhibitory effect on coagulation factor Xa, and it can be used in the study of thrombophlebitis, atherosclerosis, cerebral embolism, stroke and pulmonary embolism.
    • $35
    In Stock
    Size
    QTY
    TargetMol | Inhibitor Sale
  • Eribaxaban
    T31668536748-46-6In house
    Eribaxaban (PD348292) is an orally available factor Xa inhibitor for the prevention and treatment of venous thromboembolism.
    • $293
    In Stock
    Size
    QTY
  • Betrixaban hydrochloride(330942-05-7(free base))
    T4690
    Betrixaban hydrochloride(330942-05-7(free base)) (PRT054021 hydrochloride) is a potent, selective, and orally efficacious factor Xa (fXa) inhibitor (IC50: 1.5 nM).
    • $40
    In Stock
    Size
    QTY
  • Fidexaban
    T27318183305-24-0In house
    Fidexaban (CI1031) is a novel, potent, selective and orally active factor Xa inhibitor that has demonstrated antithrombotic activity in a variety of assays
    • $143
    In Stock
    Size
    QTY
  • EMD-503982
    T27257768370-75-8In house
    EMD-503982 is a potential Factor Xa and Factor VIIa inhibitor with potential anticancer and antitumor activity for the study of thromboembolic and neurological disorders.
    • $293 TargetMol
    In Stock
    Size
    QTY
  • Rivaroxaban Impurity
    T678531151893-81-0
    Rivaroxaban Impurity (Rivaroxaban-10) is a potent Blood-coagulation factor Xa inhibitor, IC50= 66 nM.
    • $50
    In Stock
    Size
    QTY
    TargetMol | Inhibitor Sale
  • 2-Methoxyphenothiazine
    T06421771-18-2
    2-Methoxy Phenothiazine is light yellow or light gray solid.
    • $47
    In Stock
    Size
    QTY
    TargetMol | Inhibitor Sale
  • Dechloro Rivaroxaban
    T782151415566-28-7
    Dechloro Rivaroxaban is an orally active and highly selective Factor Xa inhibitor.Dechloro Rivaroxaban has a significant inhibitory effect on free FXa in humans.Dechloro Rivaroxaban also has an inhibitory effect on thrombospondin and fibrin-associated FXa activity.
    • $33
    In Stock
    Size
    QTY
    TargetMol | Inhibitor Sale
  • Garadacimab
    T770182162134-62-3
    Garadacimab (CSL312) is a potent whole-human IgG4 monoclonal antibody targeting activation factor XII (FXIIa). Garadacimab can be used to study hereditary angioedema.
    • $313
    In Stock
    Size
    QTY
    TargetMol | Inhibitor Sale
  • Gabexate mesylate
    T037256974-61-9
    Gabexate mesylate (FOY) is a serine proteinase inhibitor used therapeutically in the treatment of pancreatitis, disseminated intravascular coagulation (DIC), and as a regional anticoagulant for hemodialysis. The drug inhibits the hydrolytic effects of thrombin, plasmin, and kallikrein, but not of chymotrypsin and aprotinin.
    • $51
    In Stock
    Size
    QTY
    TargetMol | Inhibitor Sale
  • CH3OCO-D-CHA-Gly-Arg-pNA acetate
    T7842480895-10-9
    CH3OCO-D-CHA-Gly-Arg-pNA acetate serves as a chromogenic substrate for Factor Xa, as documented in sources [1] [2].
    • $97
    5 days
    Size
    QTY
    TargetMol | Inhibitor Sale
  • Denecimig
    T825852488745-86-2
    Denecimig (Mim8), a novel bispecific human antibody mimetic of activated coagulation factor VIII, possesses both anti-FIXa and anti-FX arms. This compound robustly enhances FX activation, thereby promoting effective hemostasis both in vitro and in vivo [1].
    • Inquiry Price
    Size
    QTY
    TargetMol | Inhibitor Sale
  • D-Pro-Phe-Arg-Chloromethylketone
    T8009588546-74-1
    D-Pro-Phe-Arg-Chloromethylketone, an inhibitor of coagulation factor XII and plasma kallikrein, is significant in the regulation of thrombosis and inflammation [1].
    • Inquiry Price
    Size
    QTY
  • Letaxaban
    T68092870262-90-1
    Letaxaban (TAK-442) is a small molecule Xa factor inhibitor that can be used to study polar coronary syndromes and thrombotic blockages.
    • $210
    In Stock
    Size
    QTY
  • 5-R-Rivaroxaban
    T10174865479-71-6
    5-R-Rivaroxaban is (R)-enantiomer of Rivaroxaban. Rivaroxaban (BAY 59-7939) is a highly potent and selective, direct Factor Xa (FXa) inhibitor (IC50 0.7 nM; Ki 0.4 nM).
    • $39
    In Stock
    Size
    QTY
  • O-Desmethyl apixaban sulfate sodium
    T19488
    O-Desmethyl apixaban sulfate sodium inhibits factor X (FXa) with a Ki of 58 μM,and is a major circulating metabolite of Apixaban in humans.
    • Inquiry Price
    Size
    QTY
  • Asundexian
    T394632064121-65-7
    Asundexian (BAY-2433334) is a potent and orally active inhibitor of the coagulation factor FXIa that directly and reversibly binds to the active site of FXIa, thereby inhibiting its activity.Asundexian has an IC50 of 1 nM for human FXIa in buffer.Asundexian has antitumor activity and may be useful in studies of Acute ischemic stroke, transient ischemic attack and ischemic stroke.
    • $188
    In Stock
    Size
    QTY
    TargetMol | Inhibitor Sale
  • Rivaroxaban
    T1184366789-02-8
    Rivaroxaban (BAY 59-7939) is an orally bioavailable oxazolidinone derivative and direct inhibitor of the coagulation factor Xa with anticoagulant activity. Upon oral administration, rivaroxaban selectively binds to both free factor Xa and factor Xa bound in the prothrombinase complex. This interferes with the conversion of prothrombin (factor II) to thrombin and eventually prevents the formation of cross-linked fibrin clots. Rivaroxaban does not affect existing thrombin levels.
    • $33
    In Stock
    Size
    QTY
  • Betrixaban maleate
    T4980936539-80-9
    Betrixaban maleate is a non-vitamin K oral anticoagulant whose action is driven by the competitive and reversible inhibition of the factor Xa.
    • $37
    In Stock
    Size
    QTY
  • Fondaparinux sodium
    T4076114870-03-0
    Fondaparinux sodium (SR-90107A) is an antithrombin-dependent factor Xa inhibitor with antithrombotic activity.
    • $33
    In Stock
    Size
    QTY
  • Frunexian
    T798471803270-60-1
    Frunexian (EP-7041) is a selective and potent inhibitor of coagulation factor XI/activated factor XI, specifically targeting XIa. It demonstrates antithrombotic activity without associated bleeding risk in a rat mesenteric arterial puncture model and is applicable in extracorporeal membrane oxygenation (ECMO) research [1].
    • Inquiry Price
    Size
    QTY
  • Edoxaban
    T2368L480449-70-5
    Edoxaban (Lixiana) (DU-176) is a selective, potent and orally active factor Xa (FXa) inhibitor with K i s of 0.561 nM and 2.98 nM for free FXa and prothrombinase, respectively. Edoxaban is an anticoagulant agent and is able to be used for stroke prevention. Edoxaban is a also weak inhibitor of thrombin and factor IXaβ (FIXa), with K i s of 6.00 μM and 41.7 μM, respectively, exhibits >10 000-fold selectivity for FXa. Edoxaban has antithrombotic properties and is potential for thromboembolic diseases treatment [1] [2] [3].
    • $45
    In Stock
    Size
    QTY
  • RWJ-445167
    T12782226566-43-4
    RWJ-445167 is a thrombin and factor Xa dual inhibitor(Ki of 4.0 nM and 230 nM, respectively), with potent antithrombotic activity.
    • $2,270
    Backorder
    Size
    QTY
  • Betrixaban
    T4341330942-05-7
    Betrixaban (PRT054021) is a non-vitamin K oral anticoagulant whose action is driven by the competitive and reversible inhibition of the factor Xa [1]. It was selected among all lead compounds due to its low hERG channel affinity while sustaining its factor Xa inhibition capacity [3]. Betrixaban, now developed by Portola Pharmaceuticals Inc., is prescribed as a venous thromboembolism (VTE) prophylactic for adult patients with moderate to severe restricted motility or with other risks for VTE [2]. VTE can be manifested as deep vein thrombosis or pulmonary embolism and it is a leading cause of preventable death in hospitalized patients [4].
    • $39
    In Stock
    Size
    QTY
  • Darexaban
    T31206365462-23-3
    Darexaban (Tanexaban, YM-150) is a direct inhibitor of Factor Xa.Darexaban and Darexaban glucuronide selectively and competitively inhibit FXA and inhibit prothrombin activity at the site of blood clot (thrombus) formation. This leads to a reduction in blood clot formation in a dose-dependent manner. Reducing clotting will reduce blockages in blood flow, which may reduce the risk of myocardial infarction, unstable angina, venous thrombosis, and ischemic stroke.
    • $40
    In Stock
    Size
    QTY
  • Edoxaban Tosylate Monohydrate
    T23681229194-11-9
    Edoxaban(DU-176) is an oral factor Xa (FXa) inhibitor in clinical development for stroke prevention.
    • $43
    In Stock
    Size
    QTY
  • Apixaban
    T1736503612-47-3
    Apixaban (BMS-562247-01) is an orally active inhibitor of coagulation factor Xa with anticoagulant activity. Apixaban directly inhibits factor Xa, thereby interfering with the conversion of prothrombin to thrombin and preventing the formation of cross-linked fibrin clots.
    • $33
    In Stock
    Size
    QTY